Table 2.
Susceptibility and synergy testing results for strains used in the PK/PD modela
| Strain | Susceptibility (μg/ml) |
Synergy testing result |
|||||
|---|---|---|---|---|---|---|---|
| TLV | GEN | NAF | IMP | TLV + GEN | TLV + NAF | TLV + IMP | |
| MSSA SNL 4 | 0.5 | 0.5 | 0.5 | 0.25 | Synergy | Indifferent | Indifferent |
| MSSA SNL 9 | 0.5 | 0.5 | 0.5 | 0.015 | Synergy | Synergy | Synergy |
| MRSA SNL 96 | 0.25 | 0.25 | 32 | 32 | Synergy | Synergy | Synergy |
| MRSA SNL 98 | 0.25 | 0.5 | 128 | 64 | Indifferent | Synergy | Synergy |
| hVISA R2729 | 0.5 | 0.25 | 128 | 64 | Synergy | Synergy | Synergy |
| hVISA R3003 | 0.5 | 16 | 256 | 2 | Synergy | Synergy | Indifferent |
a
Susceptibility results are displayed only for the drugs used in the PK/PD model. Synergy results are derived from the time-kill methodology described in the text. TLV, telavancin; GEN, gentamicin; NAF, nafcillin; IMP, imipenem.